United Therapeutics (UTHR) PT Lowered to $115.00 at Credit Suisse Group

United Therapeutics (NASDAQ:UTHR) had its price target trimmed by Credit Suisse Group from $120.00 to $115.00 in a research note released on Thursday. The brokerage currently has an underperform rating on the biotechnology company’s stock.

A number of other analysts have also recently commented on UTHR. HC Wainwright reaffirmed a hold rating and issued a $95.00 price target on shares of United Therapeutics in a research note on Thursday, October 26th. ValuEngine cut United Therapeutics from a strong-buy rating to a buy rating in a research note on Friday, February 2nd. BidaskClub cut United Therapeutics from a hold rating to a sell rating in a research note on Tuesday, January 16th. TheStreet raised United Therapeutics from a c+ rating to a b rating in a research note on Friday, December 15th. Finally, Cowen reaffirmed a hold rating and issued a $129.00 price target on shares of United Therapeutics in a research note on Friday, October 27th. Five equities research analysts have rated the stock with a sell rating, five have assigned a hold rating and four have given a buy rating to the company’s stock. The company has a consensus rating of Hold and a consensus target price of $137.08.

Shares of United Therapeutics (UTHR) traded down $4.62 during mid-day trading on Thursday, hitting $117.55. The stock had a trading volume of 1,086,800 shares, compared to its average volume of 448,546. The company has a market cap of $5,282.60, a PE ratio of 11.14 and a beta of 1.26. United Therapeutics has a one year low of $112.01 and a one year high of $153.58.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings results on Wednesday, February 21st. The biotechnology company reported $3.89 EPS for the quarter, beating analysts’ consensus estimates of $3.59 by $0.30. The company had revenue of $464.70 million during the quarter, compared to analysts’ expectations of $420.55 million. United Therapeutics had a return on equity of 24.81% and a net margin of 24.22%. United Therapeutics’s revenue was up 13.6% on a year-over-year basis. During the same period in the prior year, the business posted $4.12 EPS. analysts forecast that United Therapeutics will post 11.64 EPS for the current fiscal year.

In related news, Director Christopher Causey sold 580 shares of the stock in a transaction that occurred on Thursday, December 7th. The stock was sold at an average price of $134.72, for a total transaction of $78,137.60. Following the completion of the sale, the director now directly owns 1,555 shares of the company’s stock, valued at approximately $209,489.60. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Martine A. Rothblatt sold 1,241 shares of the firm’s stock in a transaction that occurred on Thursday, November 30th. The stock was sold at an average price of $128.95, for a total transaction of $160,026.95. The disclosure for this sale can be found here. Over the last three months, insiders have sold 1,822 shares of company stock valued at $238,301. 7.80% of the stock is owned by company insiders.

Several institutional investors and hedge funds have recently modified their holdings of UTHR. Wedge Capital Management L L P NC grew its stake in shares of United Therapeutics by 2,725.8% during the 4th quarter. Wedge Capital Management L L P NC now owns 324,631 shares of the biotechnology company’s stock worth $48,029,000 after acquiring an additional 313,143 shares in the last quarter. Old Mutual Global Investors UK Ltd. grew its stake in shares of United Therapeutics by 30.3% during the 3rd quarter. Old Mutual Global Investors UK Ltd. now owns 970,846 shares of the biotechnology company’s stock worth $113,773,000 after acquiring an additional 225,953 shares in the last quarter. Renaissance Technologies LLC boosted its holdings in shares of United Therapeutics by 14.9% in the 4th quarter. Renaissance Technologies LLC now owns 1,462,378 shares of the biotechnology company’s stock valued at $216,359,000 after buying an additional 189,378 shares during the last quarter. JPMorgan Chase & Co. boosted its holdings in shares of United Therapeutics by 28.0% in the 3rd quarter. JPMorgan Chase & Co. now owns 640,475 shares of the biotechnology company’s stock valued at $76,065,000 after buying an additional 139,976 shares during the last quarter. Finally, APG Asset Management N.V. boosted its holdings in shares of United Therapeutics by 24.5% in the 3rd quarter. APG Asset Management N.V. now owns 652,000 shares of the biotechnology company’s stock valued at $76,408,000 after buying an additional 128,404 shares during the last quarter.

TRADEMARK VIOLATION NOTICE: “United Therapeutics (UTHR) PT Lowered to $115.00 at Credit Suisse Group” was originally published by Week Herald and is the sole property of of Week Herald. If you are accessing this article on another publication, it was stolen and reposted in violation of US and international trademark & copyright laws. The correct version of this article can be viewed at https://weekherald.com/2018/02/23/united-therapeutics-uthr-pt-lowered-to-115-00-at-credit-suisse-group.html.

United Therapeutics Company Profile

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).

Analyst Recommendations for United Therapeutics (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply